BIOMAT Database Logo BIOMAT Database Logo

[Erythrocyte aggregation and fibrinogen derivatives in ischemic heart disease]. 1978

V A Liusov, and A S Parfenov, and Iu B Belousov, and A V Rudakov, and V N Nechaeva

Aggregation of erythrocytes was determined in 50 patients with angina pectoris and myocardial infarction and in 20 subjects of the control group by rheoscopy after Schmid-Schoenbein. It is shown that in patients with ischemic heart disease aggregation of erythrocytes is considerably increased and the hydrodynamic strength of the aggregates is greater. The erythrocyte aggregation curve is some patients with ischemic heart disease was of a biexponential character in distinction to that in subjects of the control group, which was of the monoexponential type. It was found that the increase in the strength of the erythrocyte aggregation and in the rate of aggregate formation was due to fibrinogen and its complex compounds with decomposition products.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010783 Photometry Measurement of the various properties of light. Photometries
D011479 Protamines A group of simple proteins that yield basic amino acids on hydrolysis and that occur combined with nucleic acid in the sperm of fish. Protamines contain very few kinds of amino acids. Protamine sulfate combines with heparin to form a stable inactive complex; it is used to neutralize the anticoagulant action of heparin in the treatment of heparin overdose. (From Merck Index, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p692) Protamine,Protamine Sulfate,Protamine Chloride,Chloride, Protamine,Sulfate, Protamine
D001809 Blood Viscosity The internal resistance of the BLOOD to shear forces. The in vitro measure of whole blood viscosity is of limited clinical utility because it bears little relationship to the actual viscosity within the circulation, but an increase in the viscosity of circulating blood can contribute to morbidity in patients suffering from disorders such as SICKLE CELL ANEMIA and POLYCYTHEMIA. Blood Viscosities,Viscosities, Blood,Viscosity, Blood
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004903 Erythrocyte Aggregation The formation of clumps of RED BLOOD CELLS under low or non-flow conditions, resulting from the attraction forces between the red blood cells. The cells adhere to each other in rouleaux aggregates. Slight mechanical force, such as occurs in the circulation, is enough to disperse these aggregates. Stronger or weaker than normal aggregation may result from a variety of effects in the ERYTHROCYTE MEMBRANE or in BLOOD PLASMA. The degree of aggregation is affected by ERYTHROCYTE DEFORMABILITY, erythrocyte membrane sialylation, masking of negative surface charge by plasma proteins, etc. BLOOD VISCOSITY and the ERYTHROCYTE SEDIMENTATION RATE are affected by the amount of erythrocyte aggregation and are parameters used to measure the aggregation. Erythrocyte Aggregation, Intravascular,Agglutination, Intravascular,Intravascular Agglutination,Intravascular Erythrocyte Aggregation,Rouleaux Formation, Erythrocyte,Agglutinations, Intravascular,Aggregation, Erythrocyte,Aggregation, Intravascular Erythrocyte,Aggregations, Erythrocyte,Aggregations, Intravascular Erythrocyte,Erythrocyte Aggregations,Erythrocyte Aggregations, Intravascular,Erythrocyte Rouleaux Formation,Erythrocyte Rouleaux Formations,Formation, Erythrocyte Rouleaux,Formations, Erythrocyte Rouleaux,Intravascular Agglutinations,Intravascular Erythrocyte Aggregations,Rouleaux Formations, Erythrocyte
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

V A Liusov, and A S Parfenov, and Iu B Belousov, and A V Rudakov, and V N Nechaeva
[Erythrocyte aggregation and the blood rheological properties in chronic ischemic heart disease].
October 1980, Vrachebnoe delo,
V A Liusov, and A S Parfenov, and Iu B Belousov, and A V Rudakov, and V N Nechaeva
Fibrinogen-induced erythrocyte aggregation: erythrocyte-binding site in the fibrinogen molecule.
November 1987, Biochimica et biophysica acta,
V A Liusov, and A S Parfenov, and Iu B Belousov, and A V Rudakov, and V N Nechaeva
Plasma fibrinogen and ischemic heart disease risk factors.
January 1991, Arteriosclerosis and thrombosis : a journal of vascular biology,
V A Liusov, and A S Parfenov, and Iu B Belousov, and A V Rudakov, and V N Nechaeva
[Fibrin/fibrinogen degradation products in ischemic heart disease].
May 1989, Vrachebnoe delo,
V A Liusov, and A S Parfenov, and Iu B Belousov, and A V Rudakov, and V N Nechaeva
[Blood fibrinogen-bound sterols in ischemic heart disease].
November 1979, Vrachebnoe delo,
V A Liusov, and A S Parfenov, and Iu B Belousov, and A V Rudakov, and V N Nechaeva
Involvement of fibrinogen specific binding in erythrocyte aggregation.
April 2002, FEBS letters,
V A Liusov, and A S Parfenov, and Iu B Belousov, and A V Rudakov, and V N Nechaeva
[Circulating platelet aggregation in ischemic heart disease].
January 1981, Vojnosanitetski pregled,
V A Liusov, and A S Parfenov, and Iu B Belousov, and A V Rudakov, and V N Nechaeva
[Erythrocyte membrane fatty acids in ischemic heart disease].
January 2001, Ukrains'kyi biokhimichnyi zhurnal (1999 ),
V A Liusov, and A S Parfenov, and Iu B Belousov, and A V Rudakov, and V N Nechaeva
[Functional capacity of fibrinogen and erythrocyte aggregation in the diabetic].
January 1994, Journal des maladies vasculaires,
V A Liusov, and A S Parfenov, and Iu B Belousov, and A V Rudakov, and V N Nechaeva
[Fibrinogen as a risk factor in ischemic heart disease].
January 2003, Vojnosanitetski pregled,
Copied contents to your clipboard!